Shopping Cart
- Remove All
- Your shopping cart is currently empty
Obexelimab (XmAb5871) is a bifunctional monoclonal antibody that binds CD19 and FcyRIIb, inhibits B-cells, plasmoblasts, and plasma cells, and may be used in the study of autoimmune diseases such as systemic lupus erythematosus.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $293 | In Stock | |
5 mg | $723 | In Stock | |
10 mg | $986 | In Stock | |
25 mg | $1,490 | In Stock | |
50 mg | $1,970 | In Stock |
Description | Obexelimab (XmAb5871) is a bifunctional monoclonal antibody that binds CD19 and FcyRIIb, inhibits B-cells, plasmoblasts, and plasma cells, and may be used in the study of autoimmune diseases such as systemic lupus erythematosus. |
In vitro | Obexelimab induces the expression of genes associated with the apoptotic pathway and promotes apoptosis in B cells. [1] 10 μg/mL Obexelimab, treated for 3 min, inhibited B cell activation and its function by inhibiting BCR-mediated calcium influx and promoting phosphorylation of FcγRIIb. [2] |
In vivo | 10 mg/kg Obexelimab, injected intraperitoneally twice weekly, suppressed autoimmune responses in immunodeficient mice implanted with peripheral blood mononuclear cells (PBMC) from rheumatoid arthritis (RA) patients. [2] |
Alias | XmAb5871, AMG729, AMG 729 |
Cas No. | 1690307-05-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.